Sigyn Therapeutics (SIGY) Interest Coverage Ratio (2017 - 2025)
Sigyn Therapeutics (SIGY) posted Interest Coverage Ratio of 36.07 for Q2 2025, down 654.18% sequentially from 4.78 in Q1 2025, and up 12.46% YoY from 32.08 in Q2 2024.
Sigyn Therapeutics (SIGY) Interest Coverage Ratio (2017 - 2025) Analysis & Trends
Sigyn Therapeutics has reported Interest Coverage Ratio for 9 years, with the latest figure at 36.07 in Q2 2025.
- Quarterly Interest Coverage Ratio rose 12.46% year-over-year to 36.07 in Q2 2025, while the trailing twelve-month figure through Sep 2025 was 60.92 (up 76.14% YoY) and the FY2024 annual result came in at 0.64, up 21.62% from the prior year.
- Interest Coverage Ratio declined to 36.07 in Q2 2025 per SIGY's latest filing, from 4.78 in the prior quarter.
- Over five years, Interest Coverage Ratio peaked at 427.44 in Q4 2023 and troughed at 74.82 in Q3 2024.
- A 5-year average of 6.16 and a median of 13.3 in 2023 frame the typical range for Interest Coverage Ratio.
- The sharpest annual moves came in 2021 and 2023: Interest Coverage Ratio slumped 1865.1% in 2021, then soared 4612.02% in 2023.
- Over 5 years, Interest Coverage Ratio stood at 19.19 in 2021, then surged by 50.62% to 9.47 in 2022, then jumped by 4612.02% to 427.44 in 2023, then plunged by 105.73% to 24.48 in 2024, then plunged by 47.34% to 36.07 in 2025.
- According to Business Quant data, Interest Coverage Ratio over the past three periods registered 36.07, 4.78, and 24.48 for Q2 2025, Q1 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.40 Bn | 131.55 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 86.53 Bn | 78.54 Bn | 3.93 Bn | 117.59 |
| 3 | Argenx Se | 65.20 Bn | 60.02 Bn | 1.37 Bn | - |
| 4 | Moderna | 60.40 Bn | 55.26 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 42.17 Bn | 37.07 Bn | 1.53 Bn | 8.18 |
| 6 | Alnylam Pharmaceuticals | 31.36 Bn | 28.05 Bn | 992.69 Mn | 2.82 |
| 7 | BioNTech SE | 28.74 Bn | 10.34 Bn | 668.28 Mn | 76.86 |
| 8 | Insmed | 27.45 Bn | 26.29 Bn | 358.27 Mn | -0.08 |
| 9 | Royalty Pharma | 27.17 Bn | 26.33 Bn | - | 1.42 |
| 10 | Sigyn Therapeutics | 48,161.31 | -37,409.69 | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | -36.07 |
| Mar 31, 2025 | -4.78 |
| Dec 31, 2024 | -24.48 |
| Sep 30, 2024 | -74.82 |
| Jun 30, 2024 | -41.21 |
| Mar 31, 2024 | -11.62 |
| Dec 31, 2023 | 427.44 |
| Sep 30, 2023 | -22.70 |
| Jun 30, 2023 | -10.59 |
| Mar 31, 2023 | -13.30 |
| Dec 31, 2022 | -9.47 |
| Mar 31, 2022 | -12.51 |
| Dec 31, 2021 | -19.19 |
| Jun 30, 2021 | -8.15 |
| Mar 31, 2021 | -46.08 |
| Dec 31, 2020 | -0.98 |
| Sep 30, 2020 | -1.79 |
| Jun 30, 2020 | -2.67 |
| Mar 31, 2020 | -3.32 |
| Dec 31, 2019 | -0.19 |